SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid LeukemiaGlobeNewsWire • 07/16/24
SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid LeukemiaGlobeNewsWire • 07/08/24
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic LeukemiaGlobeNewsWire • 06/24/24
SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid LeukemiaGlobeNewsWire • 06/17/24
SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AMLGlobeNewsWire • 06/10/24
Galena Biopharma (SLS) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 05/20/24
SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/14/24
SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose LevelGlobeNewsWire • 05/01/24
SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 StudyGlobeNewsWire • 04/29/24
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/28/24
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL StudyGlobeNewsWire • 03/26/24
SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 03/19/24
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ETGlobeNewsWire • 03/19/24
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 03/15/24
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization PartnershipsGlobeNewsWire • 03/08/24
SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) ConferenceGlobeNewsWire • 03/01/24
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and TimeGlobeNewsWire • 02/29/24
SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in OncotargetGlobeNewsWire • 02/06/24
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) ConferenceGlobeNewsWire • 01/25/24
SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia PatientsGlobeNewsWire • 01/09/24